^
    Back
    Association details:
    Biomarker:Chr del(5)(q31.1)
    Cancer:Myelodysplastic Syndrome
    Drug:lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    N Engl J Med
    Title:

    Efficacy of lenalidomide in myelodysplastic syndromes

    Excerpt:
    This open-label, single-center trial evaluated the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes who had symptomatic anemia….Overall, 10 of 12 patients (83 percent) with a 5q31.1 deletion had a cytogenetic response.
    DOI:
    10.1056/NEJMoa041668